This project involves the development of a molecule (selective imidazole I1 receptor inhibitor) to treat the metabolic syndrome.

Today, nearly 30% of adults worldwide are affected by the metabolic syndrome, defined by the observation of at least 3 of the following 4 symptoms in a patient: overweight/obesity, high blood pressure, glucose intolerance and dyslipidemia.

At present, each of the symptoms is treated separately, which implies a heavy treatment for the patient who can take up to 6 drugs per day. These combinations present risks of harmful drug interactions. A single molecule to replace these combinations would be of clear benefit to patients.

Moreover, it would seem that the prevalence of this pathology is increasing among young children and adolescents, for whom therapies cannot be too heavy.

Professor Bousquet's team has already demonstrated the effect of this original molecule on model rats of this syndrome.